CP-866,087 + CP-866,087 + CP-866,087 + Placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Sexual Dysfunction, Physiological

Conditions

Sexual Dysfunction, Physiological

Trial Timeline

Jul 1, 2007 → Oct 1, 2008

NCT ID

NCT00482664

About CP-866,087 + CP-866,087 + CP-866,087 + Placebo

CP-866,087 + CP-866,087 + CP-866,087 + Placebo is a phase 2 stage product being developed by Pfizer for Sexual Dysfunction, Physiological. The current trial status is completed. This product is registered under clinical trial identifier NCT00482664. Target conditions include Sexual Dysfunction, Physiological.

What happened to similar drugs?

3 of 9 similar drugs in Sexual Dysfunction, Physiological were approved

Approved (3) Terminated (0) Active (6)

✅sildenafilPfizerApproved

✅AlfuzosinSanofiApproved

✅Levitra (Vardenafil, BAY38-9456) + PlaceboBayerApproved

🔄DapoxetineJohnson & JohnsonPhase 3

🔄AVANAFIL + placeboSanofiPhase 3

🔄tibolone + estradiol-norethisteroneOrganonPhase 3

🔄Bremelanotide + PlaceboPalatin TechnologiesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00482664	Phase 2	Completed	Jul 1, 2007	Oct 1, 2008	Sexual Dysfunction, Physiological
NCT00479492	Phase 2	Completed	Jun 1, 2007	Jan 1, 2008	Obesity

Competing Products

18 competing products in Sexual Dysfunction, Physiological

See all competitors

Product	Company	Stage	Hype Score
Dapoxetine	Johnson & Johnson	Phase 3	40
Gardasil Vaccine	Merck	Pre-clinical	26
sildenafil	Pfizer	Approved	43
sildenafil	Pfizer	Phase 2	35
PF-00446687 + Placebo	Pfizer	Phase 2	35
Bremelanotide	Pfizer	Phase 2	35
Sildenafil 100 mg + Placebo	Pfizer	Phase 2	35
Alfuzosin	Sanofi	Approved	43
AVANAFIL + placebo	Sanofi	Phase 3	40
Levitra (Vardenafil, BAY38-9456) + Placebo	Bayer	Approved	40
Placebo + 0.5 mgTestosterone + 10 mg Buspirone	Brain Biotech	Phase 2	25
Placebo + Testosterone + Buspirone hydrochloride	Brain Biotech	Phase 2	25
Placebo + Sildenafil + Testosterone	Brain Biotech	Phase 2	25
tibolone + estradiol-norethisterone	Organon	Phase 3	34
Bremelanotide + Placebo	Palatin Technologies	Phase 3	30
bremelanotide	Palatin Technologies	Phase 2	25
Bremelanotide	Palatin Technologies	Phase 3	30
EVO100 + Placebo	Evofem Biosciences	Phase 3	30